Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from Analysts at HC Wainwright
HC Wainwright started coverage on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research note issued to investors on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $30.00 target price on the stock. HC Wainwright also issued estimates for Intellia Therapeutics’ Q1 2025 earnings at ($1.40) EPS, Q2 2025 […]
HC Wainwright started coverage on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research note issued to investors on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $30.00 target price on the stock. HC Wainwright also issued estimates for Intellia Therapeutics’ Q1 2025 earnings at ($1.40) EPS, Q2 2025 […]
